Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery: a case report

Huali Hu, Shuai Zou, Ruofu Xu, Yoshinobu Ichiki, Dirk De Ruysscher, Fenglei Yu, Aihui Liao*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Patients with N3 non-small cell lung cancer (NSCLC) have unresectable tumors. Although significant progress has been made in the past decades for such tumors, the average median survival time remains at 10 months. Equally dismal long-term survival rates were reported with the average 5-year-suvival rate at 9%. Here, we report on a case of a patient with locally advanced disease that was treated with conversion therapy using targeted anti-PD-1 immunotherapy with platinum-based chemotherapy. Following this therapeutic regimen, the tumor showed a reversion to pN0 from pN3 and the patient showed a progression free survival time of at least 33 months.

Original languageEnglish
Article number590
Number of pages6
JournalAnnals of translational medicine
Issue number20
Publication statusPublished - Oct 2019


  • Conversion treatment
  • immunotherapy neoadjuvant treatment
  • N3 locally advanced NSCLC

Cite this